Ryosuke Muroyama

1.8k total citations
37 papers, 1.0k citations indexed

About

Ryosuke Muroyama is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Ryosuke Muroyama has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hepatology, 13 papers in Oncology and 13 papers in Epidemiology. Recurrent topics in Ryosuke Muroyama's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (12 papers) and Liver Disease Diagnosis and Treatment (6 papers). Ryosuke Muroyama is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (12 papers) and Liver Disease Diagnosis and Treatment (6 papers). Ryosuke Muroyama collaborates with scholars based in Japan, China and United States. Ryosuke Muroyama's co-authors include Naoya Kato, Masao Omata, Motoyuki Otsuka, Kazuhiko Koike, Takao Kawabe, Kaku Goto, Narayan Dharel, Run–Xuan Shao, Ryosuke Tateishi and Naoya Hosono and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ryosuke Muroyama

37 papers receiving 1.0k citations

Peers

Ryosuke Muroyama
Hiroyoshi Taniguchi Japan
Alla Arzumanyan United States
Myoung-Kuk Jang South Korea
Run–Xuan Shao Japan
Jean‐Pierre Couty France
Hikari Okada Japan
Hui‐Lu Zhang China
Xiaofeng Han China
Helena Reis United States
Jacopo Baglieri United States
Hiroyoshi Taniguchi Japan
Ryosuke Muroyama
Citations per year, relative to Ryosuke Muroyama Ryosuke Muroyama (= 1×) peers Hiroyoshi Taniguchi

Countries citing papers authored by Ryosuke Muroyama

Since Specialization
Citations

This map shows the geographic impact of Ryosuke Muroyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryosuke Muroyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryosuke Muroyama more than expected).

Fields of papers citing papers by Ryosuke Muroyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryosuke Muroyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryosuke Muroyama. The network helps show where Ryosuke Muroyama may publish in the future.

Co-authorship network of co-authors of Ryosuke Muroyama

This figure shows the co-authorship network connecting the top 25 collaborators of Ryosuke Muroyama. A scholar is included among the top collaborators of Ryosuke Muroyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryosuke Muroyama. Ryosuke Muroyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nakamoto, Shingo, Keita Ogawa, Junjie Ao, et al.. (2023). Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma. World Journal of Virology. 12(3). 209–220. 3 indexed citations
2.
Arai, Jun, Ken‐ichi Fujita, Kaku Goto, et al.. (2022). Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer. BMC Cancer. 22(1). 428–428. 5 indexed citations
3.
Muroyama, Ryosuke, Ryo Nakagawa, Yasuo Matsubara, et al.. (2022). Fusion HBx from HBV integrant affects hepatocarcinogenesis through deregulation of ER stress response. Virus Research. 315. 198787–198787. 8 indexed citations
4.
Arai, Jun, Kaku Goto, Ryo Nakagawa, et al.. (2021). Retinoids Decrease Soluble MICA Concentration by Inhibiting the Enzymatic Activity of ADAM9 and ADAM10. Anticancer Research. 41(5). 2307–2320. 7 indexed citations
5.
Ogasawara, Sadahisa, Keisuke Koroki, Hiroaki Kanzaki, et al.. (2021). Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver International. 42(9). 2055–2066. 15 indexed citations
6.
Fujisawa, Toshio, Takeshi Shimamura, Kaku Goto, et al.. (2020). A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Cancers. 12(5). 1294–1294. 12 indexed citations
7.
Saito, Kazuki, Shingo Nakamoto, Ryosuke Muroyama, et al.. (2020). A Novel Chiral Compound CCL441 Induces Mitotic Arrest and Apoptosis in Hepatoblastoma HepG2 Cells. 5(1). 1 indexed citations
8.
Arai, Jun, Kaku Goto, Yoko Nakajima, et al.. (2020). Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding. Cancer Immunology Immunotherapy. 70(1). 203–213. 16 indexed citations
9.
Maeda, Takahiro, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.. (2019). Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer. 19(1). 1088–1088. 29 indexed citations
10.
Nakagawa, Ryo, Ryosuke Muroyama, Chisato Saeki, et al.. (2017). miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis. Journal of Hepatology. 66(6). 1223–1230. 41 indexed citations
11.
Goto, Kaku, Dorcas A. Annan, Tomoko Morita, et al.. (2016). Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Scientific Reports. 6(1). 38407–38407. 16 indexed citations
12.
Goto, Kaku, et al.. (2015). The Characteristic Changes in Hepatitis B Virus X Region for Hepatocellular Carcinoma: A Comprehensive Analysis Based on Global Data. PLoS ONE. 10(5). e0125555–e0125555. 13 indexed citations
13.
Shibata, Chikako, Motoko Ohno, Motoyuki Otsuka, et al.. (2014). The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology. 462-463. 42–48. 99 indexed citations
14.
Sato, Masaya, Naoya Kato, Ryosuke Tateishi, et al.. (2013). IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Journal of Gastroenterology. 49(4). 748–754. 13 indexed citations
15.
Kumar, Vinod, Naoya Kato, Yuji Urabe, et al.. (2011). Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nature Genetics. 43(5). 455–458. 268 indexed citations
16.
Kato, Naoya, Ryosuke Muroyama, Run–Xuan Shao, et al.. (2009). Polymorphism of OAS‐1 determines liver fibrosis progression in hepatitis C by reduced ability to inhibit viral replication. Liver International. 29(9). 1413–1421. 23 indexed citations
17.
Dharel, Narayan, Naoya Kato, Ryosuke Muroyama, et al.. (2008). Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus†. Hepatology. 47(4). 1136–1149. 58 indexed citations
18.
Muroyama, Ryosuke, Naoya Kato, Motoyuki Otsuka, et al.. (2006). Fusion mRNA from HBV integrants is associated with hepatocarcinogenesis in human hepatoma cell line. Hepatology. 44(4). 528. 1 indexed citations
19.
Muroyama, Ryosuke, Naoya Kato, Haruhiko Yoshida, et al.. (2006). Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. Journal of Hepatology. 45(6). 805–812. 56 indexed citations
20.
Kato, Naoko, Ryosuke Muroyama, Masaru Moriyama, et al.. (2006). Absence of tyrosine kinase mutations in Japanese colorectal cancer patients. Oncogene. 26(14). 2133–2135. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyoshi Taniguchi Breakdown of academic impact, for papers by Alla Arzumanyan Breakdown of academic impact, for papers by Myoung-Kuk Jang Breakdown of academic impact, for papers by Run–Xuan Shao Breakdown of academic impact, for papers by Jean‐Pierre Couty Breakdown of academic impact, for papers by Hikari Okada Breakdown of academic impact, for papers by Hui‐Lu Zhang Breakdown of academic impact, for papers by Xiaofeng Han Breakdown of academic impact, for papers by Helena Reis Breakdown of academic impact, for papers by Jacopo Baglieri
Rankless by CCL
2026